Unrelated Peripheral Blood and Cord Blood Hematopoietic Stem Cell Transplants for Thalassemia Major

American Journal of Hematology

Volumn 75, Issue 4, 2004, Pages 209-212

  Tan, Patrick Huat Chye ^a   Hwang, William Ying Khee ^a,c   Goh, Yeow Tee ^a   Tan, Poh Lin ^b   Koh, Liang Piu ^a   Tan, Cheng Hoe ^a   Quah, Thuan Chong ^b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c Singapore Health Services   (Singapore)

Author keywords

PBSC; Thalassemia; UCBT; Unrelated

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; LYMPHOBLAST ANTIBODY; THYMOCYTE ANTIBODY;

ARTICLE; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CASE REPORT; CELL POPULATION; CELL TRANSPLANTATION; CLINICAL PROTOCOL; CORD BLOOD STEM CELL TRANSPLANTATION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MALE; ORGAN DONOR; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SIBLING; THALASSEMIA MAJOR;

BETA-THALASSEMIA; CHILD; CORD BLOOD STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 1842583988     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20015     Document Type: Article

References (12)

1. Lucarelli G, Galimberti M, Giardini C, et al. Bone marrow transplantation in thalassemia. The experience of Pesaro. Ann NY Acad Sci 1998;850:270-275.
2. Li CK, Shing MMK, Chik KW, et al. Hematopoietic stem cell transplantation for thalassemia major in Hong Kong: prognostic factors and outcome. Bone Marrow Transplant 2002;29:101-105.
3. Lucarelli G, Clift R. Bone marrow transplant for thalassemia, In: Forman SJ, Blume KJ, Thomas ED, editors. Bone marrow transplantation. Oxford, England: Blackwell Scientific Publications; 1994. p 837.
4. Nasa GL, Giardini C, Argiolu F, et al. Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood 2002;99:4350-4356.
5. Fang J, et al. Unrelated umbilical cord blood transplant for β-thalassemia major. J Trop Pediatr 2003;49(2):71-73.
6. Olivieri NF, Brittenham GM. Iron-chelatin therapy and the treatment of thalassemia. Blood 1997(Feb 1);89(3):739-761.
7. + cell dose predicts survival, post-transplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996;88:3223-3229.
8. Bittencourt H, Rocha V, Chervret S, et al. Association of CD34 cell dose with hematopoietic recovery, infections and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002;99:2726-2733.
9. Zant GV. Stem cell sources. In: Deeg HJ, editor. A guide to blood and marrow transplantation. New York: Springer-Verlag; 1999. p 27-28
10. O'Donnell LC, Elder PJ, Avalos R. How many stem cells are sufficient for engraftment? In: Bolwell BJ, editor. Current controversies in bone marrow transplantation. Totowa, NJ: Humana Press; 2000. p 9-10.
11. Gluckman E. Hematopoietic stem cell transplants using umbilical cord blood. N Eng J Med 2001;344:1860-1861.
12. Wagner JE, Barker JN. DeFor TE. et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002;100:1611-1618.